Brundin, L
Sellgren, C M
Lim, C K
Grit, J
Pålsson, E
Landén, M
Samuelsson, M
Lundgren, K
Brundin, P
Fuchs, D
Postolache, T T
Traskman-Bendz, L
Guillemin, G J
Erhardt, S
Article History
Received: 13 January 2016
Revised: 31 March 2016
Accepted: 2 June 2016
First Online: 2 August 2016
Competing interests
: SE reports having received lecture fees from Roche and an independent research grant from AstraZeneca. ML declares that over the past 36 months, he has received lecture honoraria from Biophausia Sweden, Servier Sweden, AstraZeneca and served at advisory board for Lundbeck pharmaceuticals. MS has received lecture honoraria from GlaxoSmithKline during the past 36 months. PB has received commercial support as a consultant from Renovo Neural, Roche, Teva Pharmaceutical Industries, Lundbeck A/S, AbbVie, ClearView Healthcare, FCB Health, IOS Press Partners and Capital Technologies. In addition, he has received commercial support for grants/research from Renovo and Teva/Lundbeck. BL has ownership interests in Acousort AB and Parkcell AB. SMC reports having received lecture fees from AstraZeneca and Roche. GJG, LB, SE and CKL have filed provisional patent P31294PC00 related to the findings in this article. The remaining authors declare no conflict of interest.